2017 American Transplant Congress
Reduced Conversion from IgM Anti-HLA-DSA to IgG Anti-HLA-DSA in Belatacept-Treated vs. Cyclosporine-Treated Patients in BENEFIT and BENEFIT-EXT Trials.
Post-transplant, up to 50% of recipients develop IgM DSA. Half of these patients go on to develop IgG DSA. Importantly, patients that progress to IgG…2017 American Transplant Congress
High CTLA-4 Expression and Diminished FOXO3 Expression Underlie Differential CD28 Signaling on Human Memory Th17 Cells.
Pathogen primed memory T cells can cross-react with allogeneic antigen and mediate graft rejection, a process termed allogeneic heterologous immunity. Th17 cells are pro-inflammatory CD4+…2017 American Transplant Congress
Impact of mTOR-Inhibition on Tolerance-Induction Following Heart Transplantation.
Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
Introduction: The mammalian target of rapamycin (mTOR) is a central regulator of the immune system and therefore one target of immunosuppressive drug therapy. Tolerance-inducing properties…2017 American Transplant Congress
Normothermic Donor Lung Preservation with Portable EVLP Significantly Reduces Ischemia/Reperfusion Injury in Lung Recipients by Promoting Cytokine Antagonists.
ObjectivesThe INSPIRE trial revealed significant reduction of PGD grade 3 using the Organ Care System (OCS) compared to the standard of care (SOC) for lung…2017 American Transplant Congress
Clinical Risk Factors for Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant Recipients (LTRs): Results of an International Cohort Study.
Introduction:Bronchiolitis obliterates syndrome (BOS) is a major impediment in the long term survival of LTRs. The main objective of this study was to identify infectious…2017 American Transplant Congress
Liver Retransplantation: The Largest Post MELD Single Center Experience.
Surgery, University of California Los Angeles, Los Angeles, CA
OBJECTIVE: Analyze post MELD liver retransplantation (Re-OLT) and identify recipient and donor preoperative risk factors associated with poor patient outcomes.BACKGROUND: Re-OLT is a high risk…2017 American Transplant Congress
A Non-Invasive Urinary Common Rejection Module (uCRM) Gene Expression Score Quantifies and Differentiates Kidney Transplant Injury.
1University of California San Francisco, San Francisco; 2Immucor Inc, Atlanta
We sought to investigate the use of the common rejection module (CRM) genes in the discrimination of AR, BKVN, and stable transplant phenotypes in urine…2017 American Transplant Congress
Results of the Initial Phase of the Portable Organ Care System (OCS™) Liver PROTECT Pivotal Trial.
PurposeThe OCS Liver PROTECT Trial is a prospective, international, randomized controlled trial to evaluate the impact of using portable ex-vivo warm, oxygenated blood perfusion using…2017 American Transplant Congress
Rapid Depletion of Circulating DSA and Treatment of Acute Antibody-Mediated Rejection with the Combination of CTLA-4Ig/Belatacept and Bortezomib in Mouse and Man.
1Sugery, University of Chicago, Chicago, IL; 2Surgery, The Ohio State University, Columbus, OH
Antibody mediated rejection (AMR) is a major cause of rejection, and there are limited therapeutic options for reversing alloantibody production when it is fully established.…2017 American Transplant Congress
Sulfatide-Selective NKT Cells Mediate M2 to M1 Polarization Resulting in Amelioration of Kidney Fibrosis.
Background: Macrophage subtype polarization has been suggested as a key player related to kidney fibrosis. Moreover, myofibroblast, the principal cells that produce extracellular matrix in…
- « Previous Page
- 1
- …
- 163
- 164
- 165
- 166
- 167
- …
- 181
- Next Page »